A meta-analysis of 72 randomized controlled trials (RCTs) has shown that individuals with T2DM treated with DPP-4 inhibitors face a significantly reduced risk of developing cancer compared to those receiving a placebo or other chemotherapeutic agents [160]. Here, DPP4 is linked to cancer.